Articles related to DISEASE-MODIFYING THERAPIES (DMTs)

A GLP-1 receptor agonist delivered directly into the knee joint received FDA Fast Track designation for osteoarthritis with synovitis, with phase 2a data not expected until 2027.

A 9-member Delphi panel just issued 65 implementation recommendations for anti-amyloid mAbs in private practice. Here’s what counts as practice-shaping and what’s still consensus opinion.

Researchers are increasingly studying peripheral biomarkers in high-risk populations to improve diagnosis and prediction, with standard therapies currently limited to temporary symptom relief.

“A 65% reduction in the risk of death and a statistically significant extension in median survival of over 14 months represent a clinically meaningful benefit of notable magnitude in ALS.” — Alon Ben-Noon, CEO, Neurosense Therapeutics

“Fenebrutinib represents the first potential scientific breakthrough for the PPMS community in over a decade.” — Levi Garraway, MD, PhD, Roche Chief Medical Officer

In the evolving landscape of MS treatment, the strategic choice between early aggressive and escalation therapies is critical. Understanding the nuances of patient-specific factors, such as age and disease activity, can significantly influence outcomes and guide effective management.